Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading international family stem cell bank, announces that the Board plans to propose a dividend of €0.08 per share for the year ended 31 December 2011 (2010: €0.07) , a 14% increase on last year.
For the fourth consecutive year Cryo-Save proposes a dividend increase, indicating the expected growth based on the strong impact of its new products.
Cryo-Save will allow its shareholders to choose between a distribution in shares or in cash.
Further details will be provided when the Group publishes its results for the year ended 31 December 2011 during the week commencing 19 March 2012.
Enquiries:
| Cryo-Save Group | + 31 (0) 575 548 998 |
| Arnoud van Tulder, Chief Executive Officer | |
| SPJ Financiële Communicatie (The Netherlands) | +31 (0)20 647 8181 |
| Kees Jongsma/Leon Melens |
| Daniel Stewart & Company plc (UK) | + 44 (0) 20 7776 6550 |
| Sean Lunn | |
| College Hill (UK) | + 44 (0) 20 7457 2020 |
| Rozi Morris/ Adrian Duffield |
Free footage is available on www.videobankonline.com.
About Cryo-Save (www.cryo-save.com/group)
Cryo-Save, the leading international family stem cell bank, already stores more than 204,000 samples from cord blood and umbilical cord tissue for newborns and adipose tissue for adults. These stem cells can mean the difference between life and death in the case of future threats to the health of the donors. There are already several diseases that can be treated by the use of stem cells, and the number of treatments will only increase. The use of stem cells from adipose tissue is increasingly popular in plastic surgery. Driven by its international business strategy, Cryo-Save is now represented in over 40 countries on four continents, with ultra-modern processing and storage facilities in the United States, Belgium, Germany, Dubai, India, South Africa and France (validation in progress).
